Prostemics Co. Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.31%

Prostemics Co. Ltd (203690) has an Asset Resilience Ratio of 0.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Prostemics Co. Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩132.50 Million

≈ $89.79K USD Cash + Short-term Investments

Total Assets

₩42.45 Billion

≈ $28.77 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Prostemics Co. Ltd's Asset Resilience Ratio has changed over time. See 203690 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Prostemics Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 203690 total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩132.50 Million	0.31%
Total Liquid Assets	₩132.50 Million	0.31%

Asset Resilience Insights

Limited Liquidity: Prostemics Co. Ltd maintains only 0.31% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Prostemics Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Prostemics Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	4.91%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Seegene Inc KQ:096530	Biotechnology	24.96%

Annual Asset Resilience Ratio for Prostemics Co. Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Prostemics Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.31%	₩132.50 Million ≈ $89.79K	₩42.45 Billion ≈ $28.77 Million	-14.70pp
2024-12-31	15.01%	₩9.16 Billion ≈ $6.21 Million	₩61.05 Billion ≈ $41.37 Million	-10.90pp
2023-12-31	25.91%	₩20.00 Billion ≈ $13.55 Million	₩77.19 Billion ≈ $52.31 Million	+19.82pp
2022-12-31	6.09%	₩3.14 Billion ≈ $2.13 Million	₩51.48 Billion ≈ $34.89 Million	-5.69pp
2021-12-31	11.78%	₩6.26 Billion ≈ $4.24 Million	₩53.16 Billion ≈ $36.03 Million	-15.40pp
2020-12-31	27.18%	₩16.36 Billion ≈ $11.09 Million	₩60.18 Billion ≈ $40.78 Million	-13.63pp
2019-12-31	40.81%	₩12.99 Billion ≈ $8.81 Million	₩31.84 Billion ≈ $21.58 Million	+9.51pp
2018-12-31	31.30%	₩10.43 Billion ≈ $7.07 Million	₩33.31 Billion ≈ $22.58 Million	+3.40pp
2017-12-31	27.90%	₩11.32 Billion ≈ $7.67 Million	₩40.58 Billion ≈ $27.50 Million	-25.38pp
2016-12-31	53.28%	₩25.07 Billion ≈ $16.99 Million	₩47.06 Billion ≈ $31.89 Million	+49.81pp
2015-12-31	3.47%	₩1.50 Billion ≈ $1.02 Million	₩43.28 Billion ≈ $29.33 Million	--

pp = percentage points

About Prostemics Co. Ltd

KQ:203690 Korea Biotechnology

Market Cap

$1.88 Million

₩2.78 Billion KRW

Market Cap Rank

#30197 Global

#2101 in Korea

Share Price

₩139.00

Change (1 day)

+0.00%

52-Week Range

₩139.00 - ₩139.00

All Time High

₩77250.00